<DOC>
	<DOCNO>NCT01828099</DOCNO>
	<brief_summary>The primary purpose study compare antitumor activity LDK378 versus reference chemotherapy .</brief_summary>
	<brief_title>LDK378 Versus Chemotherapy Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patient histologically cytologically confirm diagnosis nonsquamous Nonsmall cell lung cancer ( NSCLC ) Anaplastic lymphoma kinase ( ALK ) positive assess Ventana Immunohistochemistry ( IHC ) test . The test perform Novartis designate central laboratory . 2 . Patient newly diagnose stage IIIB ( candidate definitive multimodality therapy ) stage IV NSCLC relapse locally advanced metastatic NSCLC previously treat systemic anticancer therapy ( e.g . cytotoxic drug , monoclonal antibody therapy , crizotinib ALK inhibitor , targeted therapy , either experimental ) , exception neoadjuvant adjuvant therapy 3 . Patient least one measurable lesion define RECIST 1.1 . A previously irradiate site lesion may count target lesion clear sign progression since irradiation 1 . Patient known hypersensitivity excipients LDK378 ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) 2 . Patient history severe hypersensitivity reaction platinum contain drug , pemetrexed know excipients drug . 3 . Patient symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid within 2 week prior screen manage CNS symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer , ALK , LDK378</keyword>
</DOC>